<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2011">
  <stage>Registered</stage>
  <submitdate>17/06/2008</submitdate>
  <approvaldate>17/06/2008</approvaldate>
  <nctid>NCT00700193</nctid>
  <trial_identification>
    <studytitle>A Study of the Safety, Tolerability &amp; Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population</studytitle>
    <scientifictitle>An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or &gt;6 Months to &lt; 9 Years of Age).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CSLCT-FLU-04-05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Influenza Virus Vaccine
Other interventions - Influenza Virus Vaccine

Other: Group A - Equal to or greater 6 months to less than 3 years old

Other: Group B - Equal to or greater 3 years to less than 9 years old


Other interventions: Influenza Virus Vaccine
2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose

Other interventions: Influenza Virus Vaccine
2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of CSL Influenza Virus Vaccine in a Paediatric population through the assessment of the frequency of Local and general solicited symptoms, Unsolicited Adverse Events (UAE),Serious Adverse Events (SAEs)</outcome>
      <timepoint>Local &amp; general solicited symptoms for 7 days post each vaccination, UAEs for 30 days post each vaccination, SAEs for 6 months after the last primary vaccination and 6 months after the booster vaccination</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate immunogenicity response to CSL Influenza Virus Vaccine in Paediatric population according to the criteria of the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines</outcome>
      <timepoint>30 days after each vaccine dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Be healthy male or female children, aged = or &gt; 6 months to &lt; 9 years at the time of
             first study vaccination; Note: = or &gt; 6 refers to 6 calendar months

          2. Parent(s) or Guardian(s) to provide written informed consent to participate in the
             study;

          3. Be able to provide a pre-vaccination sample of up to 5mL of venous blood without undue
             distress/discomfort and

          4. Be born after a normal gestation period (between 36 and 42 weeks).</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>8</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Known allergy to eggs, chicken feathers, neomycin, polymyxin, or any components of the
             vaccine;

          2. Previous influenza vaccination;

          3. Clinical signs of active infection and/or an axillary temperature of = or &gt;37.5
             degrees Celsius or oral temperature of = or &gt;38 degrees Celsius at study entry. Study
             entry may be deferred for such individuals, at the discretion of the Principal
             Investigator;

          4. Confirmed or suspected immunosuppressive condition (including cancer), or a previously
             diagnosed (congenital or acquired) immunodeficiency disorder (including HIV);

          5. Current (or within the 90 days prior to receiving the Study Vaccine) treatment with
             immunosuppressive or immunomodulative medication, including systemic corticosteroids,
             as follows:

             Chronic or long term corticosteroids: &gt;0.5mg/kg/day of oral prednisolone or
             equivalent (Note: Use of topical or inhalant corticosteroids prior to administration
             of the Study Vaccine or throughout the Study is acceptable).

          6. Administration of immunoglobulins and/or any blood products since birth or planned
             administration of such blood products during the study period;

          7. Participation in a clinical study or use of an investigational compound (ie a new
             chemical or biological entity not registered for clinical use), within the 90 days
             prior to receiving the Study Vaccine or be planning to enter such a study during the
             study period;

          8. Current treatment with cytotoxic drugs or treatment within the 6 months prior to
             administration of the Study Vaccine;

          9. Have a known history of Guillain-Barr√© Syndrome;

         10. Have a major congenital defect or serious illness and

         11. Have a history of neurologic disorders or seizures</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>298</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Murdoch Childrens Research Institute - Melbourne</hospital>
    <postcode>3052 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Seqirus</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the Safety, Tolerability &amp; Immunogenicity of CSL
      Limited's Influenza Virus Vaccine in a two dose primary vaccination series, with a 12-month
      booster vaccination, in a paediatric population equal to or greater than 6 months to less
      than 9 years old.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00700193</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Terry M Nolan, Prof</name>
      <address>Murdoch Childrens Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>